Document:

<PAGE>

Exhibit 10.07

                          SECOND AMENDMENT TO AGREEMENT

         SECOND AMENDMENT TO AGREEMENT(the "Amendment"), between ZymeTx, Inc.
(the "Company") and the investors identified on the signature pages hereto (the
"Investors").

         WHEREAS, on October 13, 2000, the Company and the Investors entered
into a certain Registration Rights Agreement (the "RRA"); and

         WHEREAS, on October 13, 2000, the Company issued to the Investors $2
million in aggregate principal amount of the Company's 5% Senior Convertible
Debentures Due October 12, 2002 (the "Debentures"); and

         WHEREAS, on November 19, 2001, the Company and the Investors entered
into an agreement (the "Agreement") not to enforce certain rights of redemption
under the RRA and the Debentures, with effect as of August 21, 2001;

         WHEREAS, on December 17, 2001, the Company and the Investors agreed to
amend Section 2.4 of the Agreement, to provide that the Company shall have until
December 24 to prepare and file the registration statement provided for therein;
and

         WHEREAS, the Company and the Investors now agree to further amend
Section 2.4 of the Agreement, to provide that the Company shall have until
December 28 to prepare and file the registration statement provided for therein.

         THEREFORE, in consideration of the premises and mutual agreements
contained herein, and for other good and valuable consideration, the receipt and
sufficiency of which are hereby duly acknowledged, the Company and the Investors
agree as follows:

                                   ARTICLE I

         Section 2.4 shall be replaced in its entirety by the following:

         Section 2.4 New Registration Statement. ZymeTx shall prepare and file
         by December 28, 2001 a registration statement covering an additional
         6,581,582 shares of Common Stock underlying the Debentures and the New
         Warrants. Any failure of the Company to do so shall be deemed an
         Interfering Event for purposes of the RRA. After filing, the Company
         shall use its best efforts to have that registration statement declared
         effective by the Securities and Exchange Commission as soon as
         possible.

         IN WITNESS WHEREOF, this Agreement is hereby executed and delivered by
the duly authorized officers of the parties signing below.

<PAGE>

                                        ZYMETX, INC.

                                        By: /s/ Norman R. Proulx
                                           ---------------------------------
                                                Norman R. Proulx
                                                Chief Executive Officer

                                        Date:   December 21, 2001
                                             -------------------------------

                                        PALLADIN OPPORTUNITY FUND, LLC.
                                        By:  Palladin Asset Management, L.L.C.
                                             Managing Member

                                        By: /s/ Robert Chender
                                           ---------------------------------
                                                Robert Chender
                                                Managing Member

                                        Date:   December 21, 2001
                                             -------------------------------

                                        HALIFAX FUND, L.P.
                                        By:  The Palladin Group, L.P.
                                             Attorney-in-Fact

                                        By:  Palladin Capital Management, LLC
                                             General Partner

                                        By: /s/ Robert Chender
                                           ---------------------------------
                                                Robert Chender
                                                Managing Member

                                        Date:   December 21, 2001
                                             -------------------------------<PAGE>

Exhibit 10.08

                                  ZymeTx, Inc.
                         800 Research Parkway, Suite 100
                             Oklahoma City, OK 73104
                       (405) 271-1314 Fax: (405) 271-1944

December 26, 2001

Mr. Mike D. Morgan
Vice President of Business Operations
Oklahoma Medical Research Foundation
825 Northeast 13th Street
Oklahoma City, OK 73104

Dear Mr. Morgan:

With reference to your letter dated December 12, 2001, and OMRF's continuing
waiver of default on ZymeTx's past due notes payable, we propose the following:
ZymeTx will provide OMRF with a note payable in the amount of $51,390.45, which
will make us current on our past due payments. We also propose to add to the
note outstanding royalties due OMRF as of December 31, 2001 (approximately
$20,000). The note will be be dated December 31, 2001, bear interest at twelve
per cent and be payable on May 31, 2002. We will also issue a warrant for each
dollar of the note payable for the purchase of ZymeTx common stock at an
exercise price of $.30 per share. The warrants will expire on December 31, 2006.

Please indicate your acceptance of our proposal and we will execute the note and
issue the warrants by January 15, 2002.

Very truly yours,

/s/ Fred E. Hiller

Fred E. Hiller
Chief Financial Officer

ACCEPTED BY:   NAME   Mike D. Morgan
                      --------------

               TITLE  Vice President of Business Operations
                      -------------------------------------

SIGNATURE /s/ Mike D. Morgan   Date 12/26/01
          -------------------       --------<PAGE>

                                                                   Exhibit 10.44

                            WAIVER OF CERTAIN RIGHTS
                   OF THE SERIES A CONVERTIBLE PREFERRED STOCK
                      OF BEI MEDICAL SYSTEMS COMPANY, INC.

         For good and valuable consideration, the receipt and sufficiency of
which are hereby acknowledged, the undersigned Series A Convertible Preferred
stockholders of BEI Medical Systems Company, Inc., a Delaware corporation (the
"COMPANY"), constituting holders of a majority of the outstanding shares of the
Company's Series A Convertible Preferred Stock, in accordance with Section
2(b)(ii) of that certain Certificate of Designations, Preferences and Rights of
Series A Convertible Preferred Stock of the Company filed with the Secretary of
State of the State of Delaware on February 12, 2001 (THE "CERTIFICATE OF
DESIGNATIONS"), hereby agree as follows:

         1.       WAIVER. The undersigned hereby waive the right to receive any
                  preferential payment upon the occurrence of an Acquisition (as
                  that term is defined in Section 3(c)(i) of the Certificate of
                  Designations) which was not approved by the Board of Directors
                  of the Company.

         2.       LEGEND. The undersigned hereby agree on their own behalf and
                  on the behalf of their successors in interest, that any
                  certificate representing shares of the Series A Convertible
                  Preferred Stock may bear a legend reflecting this Waiver.

         3.       CONSTRUCTION. This Waiver shall be construed in accordance
                  with the laws of the State of Delaware, excluding conflicts of
                  laws principles.

         4.       COUNTERPARTS. This Waiver may be executed in several
                  counterparts, each of which shall constitute an original and
                  all of which, when taken together, shall constitute one
                  instrument.

         IN WITNESS WHEREOF, the undersigned have executed this Waiver effective
as of December 13, 2001.

                                By:  /s/ Jan Rock
                                     -------------------------------------------

                                Name:  Jan Rock
                                       -----------------------------------------

                                Title:  Managing Member, Medcapital, LLC
                                        ----------------------------------------

Shares of Series A Preferred Stock Owned: 133,333

<PAGE>

                                By:  Delta Opportunity Fund, Ltd.

                                By:  Diaz & Altschul Advisors, LLC

                                As Investment Advisor

                                Name:  Christopher S. Mooney
                                       -----------------------------------------
                                       /s/ Christopher S. Mooney

                                Title:  CFO

Shares of Series A Preferred Stock Owned: 80,000

                                By:  Delta Opportunity Fund (Institutional), LLC

                                By:  Diaz & Altschul Advisors, LLC

                                As Investment Advisor

                                Name:  Christopher S. Mooney
                                       -----------------------------------------
                                       /s/ Christopher S. Mooney

                                Title:  CFO

Shares of Series A Preferred Stock Owned: 55,334

                                By:  /s/ Jordan Davis
                                     -------------------------------------------

                                Name:  Jordan Davis
                                       -----------------------------------------

                                Title:    Radius Venture Partners
                                        ----------------------------------------
                                         Managing Partner

Shares of Series A Preferred Stock Owned: 533,334

                                By:  /s/ Robert P. Khederian
                                     -------------------------------------------

                                Name:  Robert P. Khederian
                                       -----------------------------------------

                                Title:  Individual
                                        ----------------------------------------

Shares of Series A Preferred Stock Owned: 234,483

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00032-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00032-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00032-of-00352.parquet"}]]